A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Activity of Oral AB1010 Administered at 2 Dose Levels to Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis.
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2015
At a glance
- Drugs Masitinib (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 13 Jun 2012 Results were published online in the peer-reviewed journal BMC Neurology, according to an AB Science media release.
- 17 Oct 2011 Additional trial identifiers (NCT01450488, AB04011) identified as reported by ClinicalTrials.gov.
- 10 Oct 2011 Actual end date (January 2010) added as reported by ClinicalTrials.gov.